Latest Content

AI-driven platform boosts screening capacity 41%, cuts manual review by 75% across Ochsner's 47 hospitals and 370 clinics.

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

How states can partner with free clinics and other local programs to realign incentives for uninsured patients.

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.